ClinicalTrials.gg
CompletedNCT01322594Updated Oct 23, 2013Results posted

A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease

A Phase 1 interventional study of MEDI2338 and MEDI2338 in Chronic Obstructive Pulmonary Disease, sponsored by MedImmune LLC. Completed at 4 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2013-10-23.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Enrollment
160th of 194
31 · median 137
Started
2011
with 27 others
Phase 1
42 of 284
none open now
Registered
92nd of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 160th largest by enrollment of the 194 interventional ones that give a count, is one of 28 that started in 2011, is one of 42 in phase 1, and was the 92nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

Phase I study to evaluate the safety and tolerability of single ascending intravenous doses of MEDI2338 in subjects with stable, mild to moderate chronic obstructive pulmonary disease (COPD).

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Chronic Obstructive Pulmonary Disease
  • COPD
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 40 years at time of screening.
  • Females of non- defined as surgically sterile or at least 2 years .
  • Males, unless surgically sterile, must use 2 highly effective methods of from screening through end of trial.
  • A diagnosis of mild to moderate .
  • Cigarette smoking history of ≥10 pack years.
  • Ability to understand and comply with protocol requirements, instructions and restrictions.
  • COPD symptoms adequately controlled on a therapeutic regimen that has not changed in the 4 weeks prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of any respiratory condition other than .
  • Active or history of any disease or condition that would, in the opinion of the investigator and/or medical monitor, place the subject at an unacceptable risk to participate in this study.
  • History of or suspected history of alcohol misuse or recreational substance abuse.
  • Treatment with oral or IV within 8 weeks prior to screening.
  • Concurrent enrolment in another clinical study.
  • Receipt of any drug therapy of use of any biologicals within 6 months prior to screening.
  • Known history of allergy or reaction to any component of the investigational product.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    MEDI2338 10 MG

    MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump

    Biological: MEDI2338

  • Experimental
    MEDI2338 30 MG

    MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump

    Biological: MEDI2338

  • Experimental
    MEDI2338 100 MG

    MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump

    Biological: MEDI2338

  • Experimental
    MEDI2338 300 MG

    MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump

    Biological: MEDI2338

  • Experimental
    MEDI2338 1000 MG

    MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump

    Biological: MEDI2338

  • Placebo comparator
    Placebo

    Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump

    Other: Placebo

Interventions

  • BiologicalMEDI2338

    MEDI2338 single intravenous (IV) dose (lowest dose)

  • BiologicalMEDI2338

    MEDI2338 single IV dose (next highest dose)

  • BiologicalMEDI2338

    MEDI2338 single IV dose (next highest dose)

  • BiologicalMEDI2338

    MEDI2338 single IV dose (next highest dose)

  • BiologicalMEDI2338

    MEDI2338 single IV dose (highest dose)

  • OtherPlacebo

    Placebo single IV dose

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events

    Number of participants experiencing adverse events (includes both adverse events and serious adverse events)

    Time frame: Days 1 - 92

  2. Incidence of Serious Adverse Events

    Number of participants experiencing serious adverse events

    Time frame: Days 1 - 92

  3. Incidence of Clinically Significant Hematology Laboratory Results

    Number of participants experiencing clinically significant hematology laboratory results. A clinically significant hematology laboratory result is defined as an abnormal hematology laboratory result that results in a treatment-emergent adverse event.

    Time frame: Days 1 - 92

  4. Incidence of Clinically Significant Electrocardiogram Results

    Number of participants experiencing clinically significant electrocardiogram results. A clinically significant electrocardiogram result is defined as an abnormal electrocardiogram result that results in a treatment-emergent adverse event.

    Time frame: Days 1 - 92

  5. Incidence of Clinically Significant Vital Signs Results

    Number of participants experiencing clinically significant vital signs results. A clinically significant vital signs result is defined as an abnormal vital signs result that results in a treatment-emergent adverse event.

    Time frame: Days 1 - 92

  6. Incidence of Clinically Significant Serum Chemistry Laboratory Results

    Number of participants experiencing clinically significant serum chemistry laboratory results. A clinically significant serum chemistry laboratory result is defined as an abnormal serum chemistry laboratory result that results in a treatment-emergent adverse event.

    Time frame: Days 1 - 92

Secondary outcomes

  1. Area Under the Serum Concentration-Time Curve From Time Zero to Infinity

    Area under the serum concentration-time curve from time zerio to infinity of MEDI2338

    Time frame: Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)

  2. Area Under the Serum Concentration-Time Profile From Time Zero to the Last Measurable Time Point

    Area under the serum concentration-time profile from time zero to the last measurable time point of MEDI2338

    Time frame: Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)

  3. Incidence of Anti-drug Antibodies (ADA) to MEDI2338

    Number of participants with ADA to MEDI2338

    Time frame: Days 1, 57, and 92

  4. Observed Maximum Concentration (Cmax)

    Cmax of MEDI2338

    Time frame: Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)

  5. Apparent Terminal Elimination Phase Half-life (t1/2)

    t1/2 of MEDI2338

    Time frame: Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)

  6. Clearance (CL)

    CL of MEDI2338

    Time frame: Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)

07

Results

Posted Oct 23, 2013

Participant flow

A total of 31 participants provided written informed consent and participated in the study at 3 sites in South Africa (2 sites) and the United Kingdom (1 site) between 24Feb2011 and 25Nov2011.

Participant flow — Overall Study
MilestonePlaceboMEDI2338 10 MGMEDI2338 30 MGMEDI2338 100 MGMEDI2338 300 MGMEDI2338 1000 MG
Started633676
Completed633676
Not completed000000

Outcome measures

PrimaryIncidence of Adverse Events

Number of participants experiencing adverse events (includes both adverse events and serious adverse events)

Time frame:
Days 1 - 92
Reported as:
Number · Participants
Incidence of Adverse Events
ParticipantsMEDI2338 10 MGMEDI2338 30 MGMEDI2338 100 MGMEDI2338 300 MGMEDI2338 1000 MGPlacebo
Incidence of Adverse Events336756
PrimaryIncidence of Serious Adverse Events

Number of participants experiencing serious adverse events

Time frame:
Days 1 - 92
Reported as:
Number · Participants
Incidence of Serious Adverse Events
ParticipantsMEDI2338 10 MGMEDI2338 30 MGMEDI2338 100 MGMEDI2338 300 MGMEDI2338 1000 MGPlacebo
Incidence of Serious Adverse Events000000
PrimaryIncidence of Clinically Significant Hematology Laboratory Results

Number of participants experiencing clinically significant hematology laboratory results. A clinically significant hematology laboratory result is defined as an abnormal hematology laboratory result that results in a treatment-emergent adverse event.

Time frame:
Days 1 - 92
Reported as:
Number · Participants
Incidence of Clinically Significant Hematology Laboratory Results
ParticipantsMEDI2338 10 MGMEDI2338 30 MGMEDI2338 100 MGMEDI2338 300 MGMEDI2338 1000 MGPlacebo
Incidence of Clinically Significant Hematology Laboratory Results000000
PrimaryIncidence of Clinically Significant Electrocardiogram Results

Number of participants experiencing clinically significant electrocardiogram results. A clinically significant electrocardiogram result is defined as an abnormal electrocardiogram result that results in a treatment-emergent adverse event.

Time frame:
Days 1 - 92
Reported as:
Number · Participants
Incidence of Clinically Significant Electrocardiogram Results
ParticipantsMEDI2338 10 MGMEDI2338 30 MGMEDI2338 100 MGMEDI2338 300 MGMEDI2338 1000 MGPlacebo
Incidence of Clinically Significant Electrocardiogram Results000001
PrimaryIncidence of Clinically Significant Vital Signs Results

Number of participants experiencing clinically significant vital signs results. A clinically significant vital signs result is defined as an abnormal vital signs result that results in a treatment-emergent adverse event.

Time frame:
Days 1 - 92
Reported as:
Number · Participants
Incidence of Clinically Significant Vital Signs Results
ParticipantsMEDI2338 10 MGMEDI2338 30 MGMEDI2338 100 MGMEDI2338 300 MGMEDI2338 1000 MGPlacebo
Incidence of Clinically Significant Vital Signs Results000000
PrimaryIncidence of Clinically Significant Serum Chemistry Laboratory Results

Number of participants experiencing clinically significant serum chemistry laboratory results. A clinically significant serum chemistry laboratory result is defined as an abnormal serum chemistry laboratory result that results in a treatment-emergent adverse event.

Time frame:
Days 1 - 92
Reported as:
Number · Participants
Incidence of Clinically Significant Serum Chemistry Laboratory Results
ParticipantsMEDI2338 10 MGMEDI2338 30 MGMEDI2338 100 MGMEDI2338 300 MGMEDI2338 1000 MGPlacebo
Incidence of Clinically Significant Serum Chemistry Laboratory Results000000
SecondaryArea Under the Serum Concentration-Time Curve From Time Zero to Infinity

Area under the serum concentration-time curve from time zerio to infinity of MEDI2338

Time frame:
Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)
Reported as:
Mean · ng x day/mL
Area Under the Serum Concentration-Time Curve From Time Zero to Infinity
ng x day/mLMEDI2338 10 MGMEDI2338 30 MGMEDI2338 100 MGMEDI2338 300 MGMEDI2338 1000 MGPlacebo
Area Under the Serum Concentration-Time Curve From Time Zero to Infinity27550.5 ± 8163.6104751.1 ± 40826.2281781.5 ± 61554.1915668.6 ± 342545.73081728.5 ± 846989.4—
SecondaryArea Under the Serum Concentration-Time Profile From Time Zero to the Last Measurable Time Point

Area under the serum concentration-time profile from time zero to the last measurable time point of MEDI2338

Time frame:
Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)
Reported as:
Mean · ng x day/mL
Area Under the Serum Concentration-Time Profile From Time Zero to the Last Measurable Time Point
ng x day/mLMEDI2338 10 MGMEDI2338 30 MGMEDI2338 100 MGMEDI2338 300 MGMEDI2338 1000 MGPlacebo
Area Under the Serum Concentration-Time Profile From Time Zero to the Last Measurable Time Point24427.8 ± 8086.487549.7 ± 31391.2250155.6 ± 40613.8846433.3 ± 303849.82909818.8 ± 812729.7—
SecondaryIncidence of Anti-drug Antibodies (ADA) to MEDI2338

Number of participants with ADA to MEDI2338

Time frame:
Days 1, 57, and 92
Reported as:
Number · Participants
Incidence of Anti-drug Antibodies (ADA) to MEDI2338
ParticipantsMEDI2338 10 MGMEDI2338 30 MGMEDI2338 100 MGMEDI2338 300 MGMEDI2338 1000 MGPlacebo
Incidence of Anti-drug Antibodies (ADA) to MEDI233800000—
SecondaryObserved Maximum Concentration (Cmax)

Cmax of MEDI2338

Time frame:
Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)
Reported as:
Mean · ng/mL
Observed Maximum Concentration (Cmax)
ng/mLMEDI2338 10 MGMEDI2338 30 MGMEDI2338 100 MGMEDI2338 300 MGMEDI2338 1000 MGPlacebo
Observed Maximum Concentration (Cmax)2458.0 ± 589.19722.2 ± 4376.827122.6 ± 2845.9106042.5 ± 23883.9337004.5 ± 51793.8—
SecondaryApparent Terminal Elimination Phase Half-life (t1/2)

t1/2 of MEDI2338

Time frame:
Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)
Reported as:
Mean · Days
Apparent Terminal Elimination Phase Half-life (t1/2)
DaysMEDI2338 10 MGMEDI2338 30 MGMEDI2338 100 MGMEDI2338 300 MGMEDI2338 1000 MGPlacebo
Apparent Terminal Elimination Phase Half-life (t1/2)34.85 ± 5.3040.85 ± 3.5128.46 ± 3.3726.76 ± 5.5424.87 ± 3.27—
SecondaryClearance (CL)

CL of MEDI2338

Time frame:
Pre-dose (Day 1) and post-dose (Days 1 [end of infusion, and 30 minutes and 1, 3, 8, and 24 hours postinfusion], 2, 3, 5, 8, 10, 15, 22, 29, 36, 43, 57, 71, and 92)
Reported as:
Mean · L/Days
Clearance (CL)
L/DaysMEDI2338 10 MGMEDI2338 30 MGMEDI2338 100 MGMEDI2338 300 MGMEDI2338 1000 MGPlacebo
Clearance (CL)0.387 ± 0.1250.312 ± 0.0990.365 ± 0.0710.360 ± 0.1100.346 ± 0.097—

Adverse events

Collected over Days 1-92. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/6 (0%)6/6 (100%)
MEDI2338 10 MG—0/3 (0%)3/3 (100%)
MEDI2338 30 MG—0/3 (0%)3/3 (100%)
MEDI2338 100 MG—0/6 (0%)6/6 (100%)
MEDI2338 300 MG—0/7 (0%)7/7 (100%)
MEDI2338 1000 MG—0/6 (0%)5/6 (83.3%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboMEDI2338 10 MGMEDI2338 30 MGMEDI2338 100 MGMEDI2338 300 MGMEDI2338 1000 MG
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/60/32/31/61/71/6
CoughRespiratory, thoracic and mediastinal disorders0/62/31/30/61/70/6
BradycardiaCardiac disorders0/60/30/32/60/71/6
ToothacheGastrointestinal disorders0/61/30/31/60/70/6
NasopharyngitisInfections and infestations0/60/31/30/60/71/6
SinusitisInfections and infestations2/60/30/30/60/70/6
ContusionInjury, poisoning and procedural complications1/60/31/30/60/70/6
LacerationInjury, poisoning and procedural complications2/60/30/30/61/70/6
Muscle spasmsMusculoskeletal and connective tissue disorders0/60/31/30/61/70/6
DizzinessNervous system disorders0/60/31/32/61/71/6

Baseline characteristics

Age Continuous
Age Continuous(Years)PlaceboMEDI2338 10 MGMEDI2338 30 MGMEDI2338 100 MGMEDI2338 300 MGMEDI2338 1000 MGTotal
Mean61.3 ± 8.057.0 ± 4.059.7 ± 11.060.3 ± 7.155.1 ± 5.360.8 ± 6.059.1 ± 6.8
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMEDI2338 10 MGMEDI2338 30 MGMEDI2338 100 MGMEDI2338 300 MGMEDI2338 1000 MGTotal
Female41222011
Male22145620
08

Study locations

4 sites
  • Research Site
    Bloemfontein, 9300, South Africa
  • Research Site
    George, 6529, South Africa
  • Research Site
    Port Elizabeth, 6045, South Africa
  • Research Site
    Harrow, HA1 3UJ, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Nov 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2011
First posted
Mar 24, 2011
Start
Mar 2011
Primary completionActual
Nov 2011
CompletionActual
Dec 2011
Results first posted
Oct 23, 2013
Last update
Oct 23, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01322594
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Mar 24, 2011
Start date
Mar 2011
Primary completion
Nov 2011
Completion
Dec 2011
Results posted
Oct 23, 2013
Last update
Oct 23, 2013

Study contacts

Edward Piper, MBBS
study director · MedImmune Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camoteskimab

Start the discussion